Background
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults, and is characterized by various symptoms, including progressive muscular weakness, fatigue, and myotonia [
1]. These symptoms often affect patients’ lives, including daily activities and social participation, which in turn negatively affect the quality of life (QoL) [
2,
3]. Generally, symptom severity is considered the strongest predictor of patients’ QoL [
4]. Functional impairment is one of the major factors that affect activities of daily living and social participation in neuromuscular disorders; however, cognitive, psychosocial, and subjective factors also strongly contribute to QoL [
5‐
8]. As illustrated by the disability paradox, patients with severe disability do not necessarily experience worse QoL, which highlights the influence of one’s personal disability experience [
9,
10]. Such phenomenon suggests that subjective experience of a disorder, including estimation of symptoms by patients and psychological adjustment, may be an essential factor of their QoL [
11]. Most validated QoL measures, including the 36-Item Short Form Health Survey (SF-36), are generic measures used in people with various conditions [
12]. Whereas generic measures are useful to evaluate QoL in comparison to general population, disease-specific measures (e.g., Individualized Neuromuscular Quality of Life [INQoL] questionnaire) have advantages to capture experience in individuals with muscular dystrophies [
2,
13].
Recently, patient-reported outcomes have increasingly been considered important in clinical trials [
2,
14]. Although the symptom severity has been well studied for neuromuscular disorders, the impact of patients’ subjective assessment of difficulties in activities and participation and the perceived importance of these difficulties on their QoL has not been well investigated. Furthermore, the assessment of symptoms by a clinician and subjective evaluation of symptoms by patients may differ [
15]. Therefore, patients’ QoL could be affected by their subjective evaluation of symptom severity, limitations in activities, and restrictions on participation associated with muscular diseases [
16,
17]. Consequently, even for patients experiencing symptoms of similar severity, QoL may differ depending on the restrictions experienced and the perceived importance of these activities and participation. In the current study, we tested the hypothesis that subjective symptom impact will contribute to QoL even after controlling for functional impairment in Japanese patients with DM1.
Results
Seventy-seven patients with genetically confirmed DM1 were included in this study (Table
1). The overall QoL was significantly correlated to patients’ subjective symptom impact, except for double vision (
p = 0.062) (Table
2). Functional impairment was also moderately correlated with QoL (
rho = 0.51 [95% CI: 0.32, 0.66],
p < 0.001).
Table 1
Demographic and clinical variables of the patients
Sex (male/female) | 36/41 [female 53.2] |
Age | 47.3 (10.5) |
Years of education | 13.5 (1.8) |
Onset age | 29.7 (13.1) |
Disease duration (years) | 17.5 (11.1) |
Number of CTG repeatsa) | 689.8 (447.6) |
Employment | 29 [37.7] |
Symptom impact |
Weakness | 54.1 (26.0) |
Pain | 22.7 (27.9) |
Fatigue | 46.6 (27.4) |
Myotonia | 36.3 (30.8) |
Droopy eyelids | 12.6 (24.0) |
Double vision | 12.6 (21.9) |
Swallowing difficulty | 29.4 (26.2) |
Overall QoL | 46.4 (23.0) |
Table 2
Spearman’s correlation coefficients (95% CI) between subjective symptom impact and overall QoL
Weakness | 0.43*** | 0.66*** | 0.46*** | 0.36** | 0.16 | 0.41*** | 0.86*** |
(0.23, 0.60) | (0.51, 0.77) | (0.27, 0.62) | (0.15, 0.54) | (−0.06, 0.37) | (0.20, 0.58) | (0.78, 0.91) |
Pain | | 0.63*** | 0.51*** | 0.33** | 0.32** | 0.32** | 0.58*** |
| (0.48, 0.75) | (0.32, 0.66) | (0.12, 0.52) | (0.11, 0.51) | (0.11, 0.51) | (0.41, 0.71) |
Fatigue | | | 0.53*** | 0.30** | 0.23* | 0.42*** | 0.75*** |
| | (0.35, 0.68) | (0.08, 0.49) | (0.01, 0.43) | (0.21, 0.59) | (0.63, 0.83) |
Myotonia | | | | 0.25* | 0.31** | 0.47*** | 0.58*** |
| | | (0.03, 0.45) | (0.10, 0.50) | (0.27, 0.62) | (0.41, 0.71) |
Droopy eyelids | | | | | 0.42*** | 0.27* | 0.33** |
| | | | (0.22, 0.59) | (0.05, 0.47) | (0.12, 0.52) |
Double vision | | | | | | 0.23* | 0.21 |
| | | | | (0.01, 0.44) | (−0.01, 0.42) |
Swallowing difficulty | | | | | | | 0.39*** |
| | | | | | (0.19, 0.57) |
Demographic and clinical variables were entered into Model 1, and overall QoL was significantly explained by disease duration and functional impairment (Table
3). Longer disease duration and moderate to severe functional impairment are associated with lower QoL (Table
3). The subjective symptom impact was then added as an explanatory variable (Model 2), and the subjective impact of weakness, fatigue and myotonia explained a significant proportion of the variance in overall QoL, even after controlling for demographic variables and functional impairment (Table
3). Higher subjective symptom impacts of weakness, fatigue, and myotonia were associated with lower QoL. The Nagelkerke’s pseudo
R2 that reflects explained variance in the overall QoL was high in Model 2. The AIC also supported the better fit of the model. VIF values for multicollinearity were not greater than the threshold in both Models 1 and 2 (VIF < 3.0).
Table 3
Associations between explanatory variables and overall QoL in DM1
Demographic variables and functional impairment |
Sex | −0.11 (− 0.47, 0.26) | 0.570 | 0.02 (− 0.18, 0.23) | 0.834 |
Age | 0.08 (−0.14, 0.30) | 0.485 | −0.02 (− 0.15, 0.10) | 0.722 |
Years of education | 0.05 (−0.16, 0.26) | 0.616 | 0.00 (−0.11, 0.12) | 0.982 |
Disease duration | 0.40 (0.20, 0.59) | < 0.001 | 0.12 (0.00, 0.23) | 0.047 |
Number of CTG repeats | −0.08 (−0.29, 0.12) | 0.421 | −0.06 (− 0.17, 0.05) | 0.317 |
Functional impairment | 0.82 (0.40, 1.23) | < 0.001 | 0.31 (0.07, 0.56) | 0.014 |
Subjective symptom impact |
Weakness | | 0.47 (0.30, 0.64) | < 0.001 |
Pain | | | 0.09 (−0.05, 0.23) | 0.228 |
Fatigue | | | 0.22 (0.06, 0.38) | 0.009 |
Myotonia | | 0.16 (0.02, 0.29) | 0.029 |
When we included all seven symptoms of the INQoL for exploratory purpose (i.e., weakness, pain, fatigue, myotonia, droopy eyelids, double vision, and swallowing difficulty), the significant explanatory variables were the same as shown in Table
3. The remaining three symptom scores did not significantly explain the additional variance of QoL when we added all subjective symptom variables to Model 2 (droopy eyelids:
p = 0.43; double vision:
p = 0.68; swallowing difficulty:
p = 0.79).
Discussion
The subjective symptom impact explained a significant proportion of the overall QoL among patients with DM1, after controlling for demographic variables and functional impairment. Our findings are consistent with those of previous studies, which reported the association of disease duration and functional impairment with QoL [
25‐
27]; however, the relative contribution of these variables was limited when subjective symptom impact was explained. In fact, a substantial variance in QoL was explained by patients’ subjective evaluation of the burden caused by muscular weakness, fatigue, and myotonia. Of these subjective factors, muscle weakness was the strongest predictor of QoL among the symptoms examined in this study.
Most subjective symptom impacts were moderately to strongly associated with overall QoL measured by the INQoL. Most activities of daily living were strongly affected by muscle weakness in patients with neuromuscular diseases, which naturally worsens QoL, and fatigue and myotonia were associated with social participation and daily activities [
28]. In contrast, the correlation between double vision and QoL was weak and not significant in this study. This may be because it was the least frequent symptom among those evaluated in the INQoL, consistent with a previous report [
23].
Because QoL is a subjective phenomenon, patients’ evaluation of symptoms constitutes an important part of QoL, in addition to the objective assessment of disease severity [
2,
3]. Further, the subjective evaluation of the symptom impact may also differ by symptoms [
28]. The regression models showed that subjective symptom impact of muscular weakness, fatigue, and myotonia explained additional variance in QoL even after controlling for demographic and clinical variables and functional impairment. The results showed that the subjective symptom impact of these domains uniquely contributed to patients’ QoL, suggesting the relative importance of these symptoms in understanding QoL in patients with DM1. Thus, reducing the burden of these symptoms is an important target for interventions to improve QoL in patients with myotonic dystrophy. In contrast to previous studies [
23,
29], here, the CTG repeat length was not associated with overall QoL and symptoms. The discrepancy in the results may be caused by differences in the methods used to measure the repeat length and ambiguity in the CTG repeat length measurements caused by somatic mosaicism. In addition, the age-related expansion of the repeat length, which is due to somatic instability confounding with patient’s age, also influence the estimation of the measurements. Such characteristics may weaken the relationship between CTG repeat and overall QoL in the current study.
Our study suggests the significant effects of subjective symptom impact on QoL among patients with DM1, which might account for the disparity between objective disease severity progression and QoL that has been reported in a few longitudinal studies [
11,
30,
31]. It is possible that QoL and symptom impact could be influenced by a response shift phenomenon, which is defined as a change in internal standards [
3,
32]. Patients’ perceived impact of a disease is an important mediator of QoL, which may explain the noted variation in QoL among patients with symptoms of similar severity. In fact, disease perception is one of the determinants of psychological distress and/or coping [
7,
33]. Therefore, although definitive evidence for the effectiveness of psychosocial interventions to improve disease perception in patients with muscular diseases is unavailable [
34], it is plausible that psychosocial interventions could optimize QoL in these patients [
35,
36]. A large international study demonstrated that cognitive behavior therapy for patients with myotonic dystrophy improved physical activity and participation, but it did not improve their QoL and disease burden [
37]. Although such results were affected by the fact that the intervention did not focus on subjective disease burden and QoL, more direct interventions may be needed [
35].
In summary, our findings indicate that subjective symptom impact and functional impairment are independent features associated with QoL among Japanese patients with DM1.
Limitations
The limitations of our study should be acknowledged. First, although the INQoL covers the major components of QoL for patients with DM1, other contributing factors could affect QoL. Recently, the Myotonic Dystrophy Health Index, which measures the burden of disease in myotonic dystrophy, has been validated in several languages [
36,
38‐
40]. The INQoL is a measure of how disease symptoms affect the patient’s perspective of their disease burden [
18,
19]. Thus, combining the two instruments may be desirable to determine patients’ subjective experiences of the disease better. Second, we could not examine environmental factors, such as social and welfare support, that could affect patients’ QoL; these factors are known to affect patients’ QoL [
6]. Third, cognitive impairment, disease awareness, and apathy, which are associated with disease severity, may have partially moderated the associations between subjective evaluation of disease impact and QoL [
15,
41,
42]. Lastly, the QoL measures developed using item response theory or Rasch models, such as Quality of Life in Genetic Neuromuscular Disease Questionnaire [
43,
44], would be more appropriate to obtain precise estimates for these associations.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.